Profile Details

Create Project

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Hire Dr. Mary A.

United States

Profile Summary

My thesis work focused on understanding the mechanism of chronic allograft rejection. Transplant recipients development anti-HLA antibodies and this is associated with transplant atherosclerosis, a manifestation of chronic allograft rejection. The primary goal of my Ph.D. thesis was to characterize targets in endothelial cells (ECs), which may be involved in mediating HLA class I-induced antibody mediated allograft rejection. Currently, I am focused on two projects. In the first, I am studying how mammalian target of rapamycin (mTOR) controls the growth of new blood vessels in malignant diseases such as cancer. The data from this project highlights that the SDF-1/CXCR4 axis activates angiogenesis by utilizing a pathway that requires mTORC2 signal transduction. Furthermore, these data present a potential link between mTORC2, metabolism and angiogenesis, which deserves further exploration. In the second project, I am working on the development of a new drug-screening platform for cancer research. I am developing a novel 3D in vitro system where the tumor microenvironment is encapsulated within a bead, which is ideally suited for high-throughput screening of anti-cancer drugs.

Subject Matter Expertise

• ☆ Molecular Biology
• ☆ Proteomics
• ☆ Cell Signaling Pathways
• ☆ Cell Banking
• ☆ Antibody Engineering
• ☆ Colorectal Cancer
• ☆ Vascular Medicine
• ☆ Organ Transplant

Services

• Writing
• Consulting
• Data & AI
• Product Development

Work Experience

Postdoctoral Researcher

University of California Irvine

June 2011 - May 2015

Staff Research Associate

University of California Irvine

July 2002 - September 2005

Research Assistant

University of Colorado Health Science Center

May 2000 - July 2002

Laboratory Assistant

University of Colorado Boulder

August 1996 - May 2000

Education

Ph.D.

University of California Los Angeles

September 2005 - May 2011

B.A.

University of Colorado Boulder

August 1996 - May 2000

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

Popson, S.A., Ziegler, M.E., Chen, X., Holderfield, M.T., Shaaban, C.I., Fong, A.H., Welch-Reardon, K.M., Papkoff, J., Hughes, C.C.W.(2014). Interferon-induced transmembrane protein 1 regulates endothelial lumen formation during angiogenesis . Arteriosclerosis, Thrombosis, and Vascular Biology. 34. (5). p. 1011-1019.

Jin, Y.-P., Valenzuela, N.M., Ziegler, M.E., Rozengurt, E., Reed, E.F.(2014). Everolimus inhibits anti-HLA i antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus . American Journal of Transplantation. 14. (4). p. 806-819.

Tomita, H., Ziegler, M.E., Kim, H.B., Evans, S.J., Choudary, P.V., Li, J.Z., Meng, F., Dai, M., Myers, R.M., Neal, C.R., et al.(2013). G protein-linked signaling pathways in bipolar and major depressive disorders . Frontiers in Genetics. 4. (DEC).

Ziegler, M.E., Souda, P., Jin, Y.-P., Whitelegge, J.P., Reed, E.F.(2012). Characterization of the endothelial cell cytoskeleton following HLA class I ligation . PLoS ONE. 7. (1).

Ziegler, M.E., Jin, Y.-P., Young, S.H., Rozengurt, E., Reed, E.F.(2012). HLA class I-mediated stress fiber formation requires ERK1/2 activation in the absence of an increase in intracellular Ca2+ in human aortic endothelial cells . American Journal of Physiology - Cell Physiology. 303. (8).

Ziegler, M.E., Chen, T., Leblanc, J.F., Wei, X., Gjertson, D.W., Li, K.-C., Khalighi, M.A., Lassman, C.R., Veale, J.L., Gritsch, H.A., et al.(2011). Apolipoprotein A1 and C-terminal fragment of α-1 antichymotrypsin are candidate plasma biomarkers associated with acute renal allograft rejection . Transplantation. 92. (4). p. 388-395.